These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21785750)

  • 41. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
    Valensi P; de Pouvourville G; Benard N; Chanut-Vogel C; Kempf C; Eymard E; Moisan C; Dallongeville J
    Diabetes Metab; 2015 Jun; 41(3):231-8. PubMed ID: 25976701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus.
    Kim MH; Lee MK
    Korean Diabetes J; 2010 Feb; 34(1):2-9. PubMed ID: 20532013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Dhillon S
    Drugs; 2010 Mar; 70(4):489-512. PubMed ID: 20205490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
    Mohan V; Yang W; Son HY; Xu L; Noble L; Langdon RB; Amatruda JM; Stein PP; Kaufman KD
    Diabetes Res Clin Pract; 2009 Jan; 83(1):106-16. PubMed ID: 19097665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.
    Mistry GC; Bergman AJ; Zheng W; Hreniuk D; Zinny MA; Gottesdiener KM; Wagner JA; Herman GA; Ruddy M
    Br J Clin Pharmacol; 2008 Jul; 66(1):36-42. PubMed ID: 18503607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
    Scott R; Loeys T; Davies MJ; Engel SS;
    Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
    Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
    Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
    Rosenstock J; Zinman B
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):98-107. PubMed ID: 17940427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Goldstein BJ; Feinglos MN; Lunceford JK; Johnson J; Williams-Herman DE;
    Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
    Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
    Aschner P; Kipnes MS; Lunceford JK; Sanchez M; Mickel C; Williams-Herman DE;
    Diabetes Care; 2006 Dec; 29(12):2632-7. PubMed ID: 17130196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.